Fifteen @entity1 , with a median age of 19  years having severe @entity2150 (SAA) underwent human leucocyte antigen (HLA) identical sibling donor hematopoietic stem cell transplantation (HSCT) using conditioning regimens containing @entity786 with antithymocyte globulin (ATG) or a combination of @entity3118 and @entity786 with or without ATG during December 2007 to May 2013. @entity205 and mini @entity1499 were used as @entity2132 ( @entity2132 ) prophylaxis. Graft source included peripheral blood stem cells in 11, bone marrow in 3 and both in 1. One @entity1 had @entity177 while 14 @entity1 were engrafted with a median neutrophil and platelet engraftment time of 13.5  days. One @entity1 had secondary graft rejection. Acute @entity2132 occurred in 3 @entity1 and chronic @entity2132 in 4. One year death rate in engrafted @entity1 was 14.28  %. At a mean follow-up of 21.2  months, 12 (80  %) are alive and well. One of the donors was a @entity1 of @entity447 but the disease did not occur in the recipient. The graft was successful and the recipient is alive till date.

Improving Outcome of XXXX with HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantation: An Experience of Gujarat Cancer and Research Institute (GCRI).

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity447 :: ('MESH:D006467', 'Disease') :: ['haemophilia'] @entity2150 :: ('MESH:D000741', 'Disease') :: ['aplastic anaemia'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity177 :: ('MESH:D051437', 'Disease') :: ['primary graft failure'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['Cyclosporine'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'graft versus host disease'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']
@entity2150 :: (MESH:D000741,Disease) :: ['Aplastic Anaemia']
